CN108403725A - 用于治疗消化道溃疡的组合物及其应用 - Google Patents
用于治疗消化道溃疡的组合物及其应用 Download PDFInfo
- Publication number
- CN108403725A CN108403725A CN201810494610.XA CN201810494610A CN108403725A CN 108403725 A CN108403725 A CN 108403725A CN 201810494610 A CN201810494610 A CN 201810494610A CN 108403725 A CN108403725 A CN 108403725A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- composition
- ulcer
- bacterium
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 208000025865 Ulcer Diseases 0.000 title claims abstract description 31
- 231100000397 ulcer Toxicity 0.000 title claims abstract description 28
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 60
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 39
- 201000005917 gastric ulcer Diseases 0.000 claims abstract description 39
- 241000186660 Lactobacillus Species 0.000 claims abstract description 21
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 14
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 14
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 13
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 13
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 38
- 238000004108 freeze drying Methods 0.000 claims description 17
- 241000196324 Embryophyta Species 0.000 claims description 15
- 230000001684 chronic effect Effects 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 230000001154 acute effect Effects 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 210000000481 breast Anatomy 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 239000000905 isomalt Substances 0.000 claims description 3
- 235000010439 isomalt Nutrition 0.000 claims description 3
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims 1
- 244000005700 microbiome Species 0.000 abstract description 6
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 230000004888 barrier function Effects 0.000 abstract description 2
- 230000009545 invasion Effects 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000006378 damage Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 230000004083 survival effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 239000006193 liquid solution Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000005030 aluminium foil Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 210000002417 xiphoid bone Anatomy 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 101100001676 Emericella variicolor andK gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010017815 Gastric perforation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- -1 MDA Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010061577 Ulcer haemorrhage Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Abstract
Description
组别 | n | 损伤积分总和 | 损伤积分指数 | 损伤抑制率(%) |
模型组 | 10 | 29.80±1.44 | 2.98±1.44 | --- |
受试组 | 10 | 19.70±3.84* | 1.97±3.84* | 33.89 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810494610.XA CN108403725B (zh) | 2018-05-22 | 2018-05-22 | 用于治疗消化道溃疡的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810494610.XA CN108403725B (zh) | 2018-05-22 | 2018-05-22 | 用于治疗消化道溃疡的组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108403725A true CN108403725A (zh) | 2018-08-17 |
CN108403725B CN108403725B (zh) | 2021-02-09 |
Family
ID=63140206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810494610.XA Active CN108403725B (zh) | 2018-05-22 | 2018-05-22 | 用于治疗消化道溃疡的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108403725B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111690565A (zh) * | 2020-07-02 | 2020-09-22 | 重庆第二师范学院 | 一种益生菌及其在胃损伤中的应用 |
CN113355259A (zh) * | 2021-03-24 | 2021-09-07 | 孙长春 | 一株格氏乳杆菌及其在治疗消化性溃疡中的应用 |
CN116004475A (zh) * | 2023-02-15 | 2023-04-25 | 生合生物科技(扬州)有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
CN117683698A (zh) * | 2024-02-04 | 2024-03-12 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
CN116004475B (zh) * | 2023-02-15 | 2024-05-03 | 生合生物科技(扬州)有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101384700A (zh) * | 2005-12-22 | 2009-03-11 | 器官平衡有限责任公司 | 新的乳杆菌属菌株及其用于对抗幽门螺杆菌的用途 |
CN103648511A (zh) * | 2011-06-08 | 2014-03-19 | 有机平衡有限公司 | 喷雾干燥的乳杆菌属菌株/细胞及其对抗幽门螺杆菌的用途 |
CN107164274A (zh) * | 2017-06-15 | 2017-09-15 | 广州市微生物研究所 | 一种乳酸菌复合菌剂及其制备方法和应用 |
-
2018
- 2018-05-22 CN CN201810494610.XA patent/CN108403725B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101384700A (zh) * | 2005-12-22 | 2009-03-11 | 器官平衡有限责任公司 | 新的乳杆菌属菌株及其用于对抗幽门螺杆菌的用途 |
CN103648511A (zh) * | 2011-06-08 | 2014-03-19 | 有机平衡有限公司 | 喷雾干燥的乳杆菌属菌株/细胞及其对抗幽门螺杆菌的用途 |
CN107164274A (zh) * | 2017-06-15 | 2017-09-15 | 广州市微生物研究所 | 一种乳酸菌复合菌剂及其制备方法和应用 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111690565A (zh) * | 2020-07-02 | 2020-09-22 | 重庆第二师范学院 | 一种益生菌及其在胃损伤中的应用 |
CN113355259A (zh) * | 2021-03-24 | 2021-09-07 | 孙长春 | 一株格氏乳杆菌及其在治疗消化性溃疡中的应用 |
CN116004475A (zh) * | 2023-02-15 | 2023-04-25 | 生合生物科技(扬州)有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
CN116004475B (zh) * | 2023-02-15 | 2024-05-03 | 生合生物科技(扬州)有限公司 | 一株用于预防、辅助治疗胃部虚寒的植物乳杆菌及其应用 |
CN117683698A (zh) * | 2024-02-04 | 2024-03-12 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108403725B (zh) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11504048A (ja) | 泌尿生殖器および腸用の組成物 | |
CN107815432B (zh) | 一种人用灭活乳酸菌制剂及其用途 | |
CN108403725A (zh) | 用于治疗消化道溃疡的组合物及其应用 | |
EP2158916A1 (en) | Administration unit comprising lactic acid bacteria | |
CN102727531A (zh) | 一种对阴道炎具有治疗和预防作用的活性乳酸菌胶囊 | |
CN108635585A (zh) | 一种治疗老年性阴道炎的药物组合物及温敏缓释凝胶剂和制备方法 | |
US20230072816A1 (en) | Method To Improve The Health Of The Microbiome In A Human Gastrointestinal System And Multi-Chamber Probiotic Delivery Products Therefor | |
EP3261723B1 (en) | Probiotic lactobacillus plantarum strains for urinary tract infections | |
CN111084831A (zh) | 一种抑制阴道致病菌的抑菌组合物及其应用 | |
CN109985069B (zh) | 益生菌组合物及其用途 | |
CN103157095A (zh) | 芸豆植物凝集素在制备人用药物中的应用及其药物组合物 | |
WO2010000207A1 (zh) | 一种天然蒜素片及其制备方法 | |
CN101797269A (zh) | 一种调节女性阴道微生态的生理平衡液 | |
CN101849969A (zh) | 产酪酸有益菌在制备防治重症疾病肠道屏障损伤及损伤后并发症制剂中的应用 | |
CN116966206A (zh) | 发酵乳杆菌用于制备预防和/或治疗泻剂结肠的产品的用途 | |
CN115607577B (zh) | 一种具有缓解口腔炎症功效的益生菌剂及其制备方法和应用 | |
CN115517367B (zh) | 副干酪乳杆菌smn-lbk在制备促进肠道健康产品中的应用 | |
CN115119940A (zh) | 嗜酸乳杆菌LA85和乳双歧杆菌BLa80在抑制幽门螺旋杆菌上的应用 | |
CN109464655B (zh) | 一种防治阴道炎的外用胶囊制剂 | |
CN105749260A (zh) | 一种盐酸溶菌酶阴道片及其制备方法和应用 | |
CN102526013A (zh) | 一种药物组合物及其应用 | |
CN108815132A (zh) | 一种三氧活性油软胶囊及其制备方法与应用 | |
CN113150069B (zh) | 一种透明质酸酶抑制剂及其制备方法 | |
CN112402465B (zh) | 一种植物乳杆菌n-1在制备预防和/或改善良性前列腺增生的产品及用途 | |
CN107596075A (zh) | 一种治疗宫颈炎的药物组合物配方及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 1201-1202, 293 Workers'East Road, Jiaojiang District, Taizhou City, Zhejiang Province, 318000 Applicant after: Zhejiang Maokang Biotechnology Co.,Ltd. Applicant after: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd. Address before: Room 1201-1202, 293 Workers'East Road, Jiaojiang District, Taizhou City, Zhejiang Province, 318000 Applicant before: TAIZHOU MAIKANG BIOTECHNOLOGY Co.,Ltd. Applicant before: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190515 Address after: No. 46, Jiaojiang District, Taizhou, Zhejiang Province Applicant after: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd. Address before: Room 1201-1202, 293 Workers'East Road, Jiaojiang District, Taizhou City, Zhejiang Province, 318000 Applicant before: Zhejiang Maokang Biotechnology Co.,Ltd. Applicant before: ZHEJIANG HISUN PHARMACEUTICAL Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |